. Author manuscript; available in PMC: 2018 Jul 15.

Published in final edited form as: Clin Cancer Res. 2017 Feb 2;23(14):3859–3870. doi: 10.1158/1078-0432.CCR-16-2857

Table 1.

Clinico-pathologic features of the 35 metaplastic breast carcinomas included in this study.

Clinico-pathologic features	MBC (n=35)	MBC with chondroid metaplasia^* (n=16)	MBC with spindle cell metaplasia^* (n=10)	MBC with squamous metaplasia^* (n=9)
Histologic grade^**
1	0 (0%)	0 (0%)	0 (0%)	0 (0%)
2	5 (14%)	3 (19%)	1 (10%)	1 (11%)
3	30 (86%)	13 (81%)	9 (90%)	8 (89%)
ER status
Negative	34 (97%)	16 (100%)	10 (100%)	8 (89%)
Positive	1 (3%)	0 (0%)	0 (0%)	1 (11%)
PR status
Negative	34 (97%)	16 (100%)	10 (100%)	8 (89%)
Positive	1 (3%)	0 (0%)	0 (0%)	1 (11%)
HER2 status
Negative	34 (97%)	16 (100%)	10 (100%)	8 (89%)
Positive	1 (3%)	0 (0%)	0 (0%)	1 (11%)
Triple-negative phenotype^***	33 (94%)	16 (100%)	10 (100%)	7 (78%)

ER, estrogen receptor; MBC, metaplastic breast carcinoma; PR, progesterone receptor.

, according to the predominant cellular type, as previously described (17).

^**

, according to the Nottingham grading system (18).

^***

, lack of ER expression, PR expression and HER2 overexpression/amplification.